NovalGen is developing a platform approach to innovation.

Our approach consists of an integrated protein engineering platform adding novel attributes to bispecific molecules. One important feature of our technology, which is planned for suitable future programs, is the ability to self-regulate; something that does not exist in any class of drug currently.

Another advantage of NovalGen’s bispecific platform approach is that it can be leveraged across multiple classes of disorders, targeting large patient populations. It enables speed of innovation, and, importantly, our drugs can be manufactured reliably and consistently across a range of different pipeline products.

NovalGen is building a strong foundation and aims to shape the bispecific field and beyond for the future of oncology treatment.

Further reading

Our science

Our focus is on using bispecific antibody approaches.

Read more


Our robust pipeline comprises high value proprietary assets.

Read more